Redeye updates on Stillfront following the company's Q4-report which saw stronger EBITDA than expect...
Redeye is impressed by the strong tailwind that Waystream has at the moment.
Redeye returns with a review following BIMobject’s Q4 report which held no major surprises.
Redeye updates its estimates and base case following Sozap’s Q4 report, which showed lower sales and...
Taaleri's Q4 was a mixed bag with higher-than-anticipated carry, while investment operations fell sh...
NoHo reported Q4 EBIT 2% above Refinitiv consensus.
Redeye comments on Ultimovacs’ Q4 2022 report, and we judge that INITIUM and NIPU top-line data in H...
Q4 was surprisingly strong on all items We raise '23e-'24e adj.
Redeye adjusts its bull and bear case due to a modelling error on terminal EBIT and terminal growth ...
Redeye returns with a more in-depth take on Sedana Medical’s Q4 report.
Prostatype is making significant progress, with more than 10 Nordic clinics offering the Prostatype ...
Fortsatt leverans från bolaget Omsättningen i kvartalet uppgick till EUR 26m, vilket motsvarar en ti...
Rapport i linje med estimat Omsättningen för helåret uppgick till 129,6 mkr vs våra estimat om 128,8...
Redeye updates its estimates following Carasent’s Q4 2022 report, which showed stronger growth than ...
Fortsätter att uppvisa stark hyrestillväxt Intäkter för helåret uppgick till 296 mkr, motsvarande en...
Håller i pengarna Det siffermässiga i rapporten var odramatiskt och något bättre än det vi hade räkn...
Vaisala posted Q4 net sales roughly in line with our estimates.
Fellow Bank's top line figures were better than expected, while higher than expected opex and expect...
Endomines volumes and revenue for H2 2022 were in line with our estimates yet the profitability was ...
Finnair’s Q4 report was a bit better than expected, however we see current valuation limiting upside...
